Patients & Caregivers
If you or someone you know has been diagnosed with ovarian cancer, or
are at a high-risk for
ovarian cancer, the
right treatment path
can lead to more
positive results.
Healthcare Professionals
Learn more about HE4
and its use as an aid in
monitoring recurrence of
ovarian cancer. View
resources
including
influential research,
slide decks, patient
communications,
and more.
Take the Right Treatment Path
Each year, an estimated 22,000 women in the United States will be diagnosed with ovarian cancer.1
The symptoms of ovarian cancer are confounding, so it is hard to detect in the early stages. In fact, approximately 75% of cases are typically first diagnosed at stage III or IV. This underscores the importance of knowing the risk factors and symptoms of ovarian cancer, and when to see a doctor. However, patients who receive treatment at the onset of the cancer from gynecologic oncologist have better survival rates and reduced care-related costs.2,3
About HE4
The Fujirebio Diagnostics HE4 test has been cleared by the US Food and Drug Administration for use as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer.
